ARO-MAPT-SC

PreclinicalSmall molecule

Arrowhead Pharmaceuticals

ARO-MAPT-SC is one of 43 small molecule programs targeting Alzheimer disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer DiseaseRecruiting

Alzheimer DiseasePreclinical

Recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Dayvigo

Eisai

Approved

1 2

Leqembi

Eisai

Approved

1 3

Avelox

Victoza

Avandia

Estrace

Rifadin

Aleve

Epidiolex

Cialis

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Alzheimer Disease

NCT07221344

Clinical

Trials by Indication[1]

Alzheimer disease1 trial

A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Preclinical·NCT07221344·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARO-MAPT-SC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARO-MAPT-SC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARO-MAPT-SC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Arrowhead Pharmaceuticals

ARO-MAPT-SC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News